

Precursors of lipid metabolism for the diagnosis and treatment of cancer

What: *Asset acquisition, assignment of patent*

For whom: *Strong development & marketing partner in this field*

Technology

- Using a modified prodrug of lipid metabolism with a detectable label.
- Benefits for assignee
 - Full control over patent in Ep, US and JP
 - Technology and market securing
 - Basis for the development of a new cancer diagnostic or therapy.

Innovation

- The invention is based prodrugs are specifically enriched in tumor tissue, in which they may be detected by suitable imaging techniques. Alternatively, a prodrug comprising a therapeutic residue, such as a suitable radioactive residue, may be used for the treatment of cancer.

Application

- Diagnostic and Radiotherapy of cancer.

Developmental Status

- Lab tests, functional principals

Responsible Scientist

Prof. Dr. Sven Reske
Ulm University
Department of Diagnostic and
Interventional Radiology

Branch

Cancer Diagnostic and Cancer
Radiotherapy

Patent Status

Ep Patent is pending

Reference Number

PVAUlm453

Status: Dez-12



CTF – The R & D Company of the
Freiburg University and the Freiburg
University Medical Center



ulm university universität
uulm

Contact

Dr. Claudia Skamel
Campus Technologies Freiburg GmbH
Stefan-Meier-Str. 8 | D-79104 Freiburg
Email: Claudia.Skamel@campus-
technologies.de
Tel: +49 (0)761 203-4987
Fax: +49 (0)761 203-5021